Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Paukenschlag in USA: Cannabis-Neuregulierung durch DEA sorgt für Kursexplosion!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
33 Leser
Artikel bewerten:
(0)

AMDL Announces Teleconference to Discuss Its Second Quarter 2008 Financial Results

TUSTIN, Calif., Aug. 15 /PRNewswire-FirstCall/ -- (http://www.amdl.com/) AMDL Inc. , a world leader in specialty pharmaceuticals with operations in Shenzhen, Jiangxi and Jilin China, announced today its chief executive officer Gary Dreher and chief financial officer Akio Ariura will host a teleconference to discuss the Company's second quarter 2008 financial results. The call is scheduled for Tuesday, August 19, 2008 at 1:45 p.m. Pacific Standard Time (4:45 p.m. Eastern Time).

Existing or potential investors who would like to submit questions prior to the call can do so by emailing Kristine Szarkowitz at kszarkowitz@amdl.com.

To access the live call, please dial (877) 360-1705 in the U.S. or (706) 902-3245 outside the U.S. and reference Conference ID# 60855707 five minutes before the call begins. The conference call script will also be available on the Investor section of the AMDL web site located at http://www.amdl.com/. Click on "Investor Relations," then "Recent News" to access the Company's earnings release which was issued today, August 15, 2008, and all other accompanying financial and operating information.

About AMDL:

AMDL Inc. is a global specialty pharmaceutical company. The company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com/.

About Jade Pharmaceutical:

JPI has access to the fastest growing pharmaceutical and consumer market in the world -- China. AMDL, through its Jade subsidiaries, currently holds licenses for 133 products that are manufactured as large volume injection fluids, tablets and other related products. It currently manufactures over 20 key generic, over-the-counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

AMDL Contact: Kristine Szarkowitz Director-Investor Relationskszarkowitz@amdl.com(M) (206) 310-5323

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2008 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.